# HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma

> **NCT03216499** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 24 (actual)

## Conditions studied

- Recurrent Glioblastoma

## Interventions

- **DRUG:** HIF-2alpha Inhibitor PT2385
- **OTHER:** Pharmacological Study
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacogenomic Study

## Key facts

- **NCT ID:** NCT03216499
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-14
- **Primary completion:** 2019-08-31
- **Final completion:** 2020-06-05
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2022-05-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03216499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03216499, "HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03216499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*